AUTL   $3.72  -3.25% Market Closed After Close 3.73 0.27%

Autolus Therapeutics PLC
Last Events:

2023-08-09 Signal in Stochastic changed from bearish reversal to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-09 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: exit from the overbought zone.

2023-08-06 Signal in RSI changed from bullish weakening to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-05 Signal in Stochastic changed from bullish recovery to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: main and signal line crossing.

2023-08-05 Signal in MACD changed from bullish recovery to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: signal line crossed the middle level.

2023-08-05 Trend Power changed from medium strength to slow.

2023-08-04 Trend pattern changed from симметричный треугольник to восходящий треугольник.

2023-08-03 Signal in RSI changed from bullish recovery to bullish weakening. RSI indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: entrance to the overbought zone.


Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 10
Target Price Mean 10.40
Mean unverified/preliminary 10.40 / 10.40
Target Price Low / High 7.00 / 13.00
Median / STD DEV 11.00 / 1.90
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy ActivelyBuy
rsi Sell ActivelyBuy None
macd None None None
stoch None None None
ma20 Sell None None
ma50 ActivelyBuy None None
ma100 Buy Buy ActivelyBuy
Candlestick PatternSept. 18, 2024 Bullish Harami - consists of an unusually large black body followed by a small white body contained within large black body. It is considered as a bullish pattern when preceded by a downtrend.
ISIN US05280R1005
ceo Dr. Christian Martin Itin Ph.D.
Website https://www.autolus.com
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.